Invega Trinza Dosing Frequency
Invega Trinza (paliperidone palmitate) is administered once every 3 months (quarterly). 1
Administration Schedule
Invega Trinza must be given every 3 months as an intramuscular injection by a healthcare professional only. 1 This is the defining characteristic that distinguishes it from the monthly formulation (Invega Sustenna/PP1M).
Critical Prerequisites Before Starting
You cannot simply start a patient on Invega Trinza. The patient must first:
- Be adequately treated with the 1-month paliperidone palmitate (Invega Sustenna) for at least 4 months 1
- Have received the same dose for the last two consecutive monthly injections 2
- Demonstrate clinical stability on the monthly formulation before transitioning 2
Transition Dosing
When transitioning from monthly to quarterly dosing, initiate Invega Trinza when the next monthly dose would be due, using this conversion: 1
- 78 mg monthly → 273 mg every 3 months
- 117 mg monthly → 410 mg every 3 months
- 156 mg monthly → 546 mg every 3 months
- 234 mg monthly → 819 mg every 3 months
Note: Conversion from the 39 mg monthly dose has not been studied and should not be attempted. 1
Clinical Evidence Supporting Quarterly Dosing
The 3-month formulation has demonstrated non-inferiority to monthly dosing in preventing relapse while offering the practical advantage of fewer injections. 3 Research shows that 50% of patients withdrawn from PP3M remained relapse-free for approximately 13 months, compared to only 6 months for monthly formulations and 2 months for oral paliperidone. 4 Real-world data from Taiwan involving 4,001 patients showed that transitioning from monthly to quarterly dosing reduced hospitalization costs by approximately half and significantly decreased emergency room visits and total healthcare utilization. 5
Important Caveats
Missed doses should be avoided. 1 The long duration of action means that missing a quarterly injection has more significant implications than missing a monthly dose. If a dose is missed, refer to detailed prescribing information for management strategies rather than simply giving the next scheduled dose.
Renal impairment requires dose adjustment: Invega Trinza is not recommended for moderate to severe renal impairment (CrCl <50 mL/min). For mild impairment (CrCl 50-80 mL/min), stabilize the patient on monthly dosing first, then transition. 1